Adverse Effect Management and the Role of Immunotherapy in NMIBC

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

EP: 1.Navigating BCG Shortages in NMIBC

EP: 2.The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

EP: 3.Efficacy and Safety Data from SunRISe-1

EP: 4.Overview of the QUILT Trial in BCG-Unresponsive NMIBC

EP: 5.Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC

Now Viewing

EP: 6.Adverse Effect Management and the Role of Immunotherapy in NMIBC

EP: 7.Selecting Optimal Treatment in BCG-Unresponsive NMIBC

EP: 8.Patient Monitoring Strategies in BCG-Unresponsive NMIBC

EP: 9.Promising Developments in NMIBC

EP: 10.Key Takeaways on the Evolving NMIBC Treatment Landscape

Related Videos

Related Content

Advertisement

January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke

Check out the key regulatory decisions set to happen early this year.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD

“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.

January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke

The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.

Related Content

Advertisement

January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke

Check out the key regulatory decisions set to happen early this year.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD

“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.

January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke

The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.